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RGS proteins (Regulators of G protein Signaling) are a
recently discovered family of proteins that accelerate
the GTPase activity of heterotrimeric G protein a sub-
units of the i, q, and 12 classes. The proteins share a
homologous core domain but have divergent amino-ter-
minal sequences that are the site of palmitoylation for
RGS-GAIP and RGS4. We investigated the function of
palmitoylation for RGS16, which shares conserved ami-
no-terminal cysteines with RGS4 and RGS5. Mutation of
cysteine residues at residues 2 and 12 blocked the incor-
poration of [3H]palmitate into RGS16 in metabolic label-
ing studies of transfected cells or into purified RGS
proteins in a cell-free palmitoylation assay. The purified
RGS16 proteins with the cysteine mutations were still
able to act as GTPase-activating protein for Gia. Inhibi-
tion or a decrease in palmitoylation did not significantly
change the amount of protein that was membrane-asso-
ciated. However, palmitoylation-defective RGS16 mu-
tants demonstrated impaired ability to inhibit both Gi-
and Gq-linked signaling pathways when expressed in
HEK293T cells. These findings suggest that the amino-
terminal region of RGS16 may affect the affinity of these
proteins for Ga subunits in vivo or that palmitoylation
localizes the RGS protein in close proximity to Ga sub-
units on cellular membranes.
RGS proteins1 enhance the GTPase activity of heterotrimeric
G protein a subunits to turn off signaling between cell-surface
receptors and intracellular effectors (1). More than 20 mamma-
lian RGS proteins have been identified by virtue of a common
stretch of 125 amino acids termed the RGS box (2–3), which is
a site of interaction of RGS proteins and Gia subunits. RGS
proteins bind and stabilize Gia in its transition state (between
GTP- and GDP-bound), thus lowering the energy barrier for
GTP hydrolysis (4–6). Recently a group of proteins with a
divergent RGS domain that act exclusively on G12a and G13a to
accelerate their GTPase activity has been identified (7). Stud-
ies of reconstituted signaling pathways in cell lines, consisting
of overexpressed or endogenous receptors, RGS proteins, effec-
tors (in some cases), and endogenous G proteins, have shown
that transiently expressed RGS proteins inhibit G protein-
mediated signaling in these systems (3, 8–9).
A perplexing question is the regulation of these 20 RGS
proteins because almost all of them have powerful enzymatic
activity toward the same substrates, and many may be ex-
pressed in the same cell type. Temporal or stimulus-specific
transcriptional regulation, protein turnover, or post-transla-
tional modifications represent possible means of controlling the
availability of a particular RGS protein to preside over a G
protein-coupled signaling event at the plasma membrane. One
such modification, addressed in this report, is palmitoylation.
Palmitoylation, the reversible thioacylation of cysteine resi-
dues, occurs on several molecules involved in G protein-linked
signaling pathways. G protein-coupled receptors incorporate
[3H]palmitate upon addition of ligand (10–11). Ga proteins of
all four classes undergo palmitoylation at their amino termini
(12–13). Receptor activation leads to palmitate turnover on Gsa
and regulates its signaling (14–16). Palmitoylation may also be
involved in targeting Ga subunits to the plasma membrane
(17).
At least two RGS proteins, RGS4 and RGS-GAIP, undergo
palmitoylation in vivo. RGS-GAIP, which contains an amino-
terminal cluster of cysteines, was labeled with [3H]palmitic
acid in the membrane fraction of transfected COS-7 cells, but
no functional significance of this finding was determined (18).
RGS-GAIP was subsequently localized to the membranes of
clathrin-coated vesicles and not the plasma membrane (19).
RGS4, which shares conserved amino-terminal cysteines with
RGS5 and RGS16 (Cys-2 and Cys-12), was palmitoylated on
these residues in baculovirus-infected Sf9 insect cells (20).
However, palmitoylation was not necessary for membrane at-
tachment in yeast, and an RGS4 double cysteine mutant (Cys-
2/Cys-12) was relatively functional in yeast cells as measured
by its ability to inhibit pheromone-induced signaling (20).
RGS4 and RGS16 are highly related RGS proteins (55%
identical in their RGS domains and 42% identical in their
amino-terminal 30 amino acids) with similar GAP activity (21–
22). RGS16 was originally termed RGSr because of its abun-
dance in the murine retina (23). However, the human ortho-
logue was renamed RGS16 as it is found in many tissues (24).
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In this study, we show that RGS16 underwent palmitoylation
in vitro and in mammalian cells. Mutation of putatively palmi-
toylated cysteine residues in RGS16 did not substantially alter
their affinity for G proteins in vitro as measured by GAP
activity or their membrane attachment, but mutants showed
quantitative defects in their ability to inhibit Gi- and Gq-cou-
pled signaling pathways in vivo. These results suggest that
palmitoylation may be an important means of regulation of
RGS activity in mammalian cells.
EXPERIMENTAL PROCEDURES
Plasmids, Proteins, and Antisera—For site-directed mutagenesis of
murine RGS16, QuikChange (Stratagene), a polymerase chain reaction-
based method, was performed except that Pwo polymerase (Roche Mo-
lecular Biochemicals) was used. The following primers were used: C2A,
GCGTCCGCAACCATGGCCCGCACCCTAGCCAC, and C12A, ACCT-
TCCCCAACACCGCCCTGGAGAGAGCCAA. Mutations were con-
firmed using Applied Biosystems PRISM dye terminator cycle sequenc-
ing (Perkin-Elmer). Production of recombinant RGS16 was performed
by inducing Escherichia coli strain BL21(DE3) containing pET15B-
RGS16 with isopropyl b-D-thiogalactopyranoside as described (23). Fol-
lowing sonication, RGS16 was purified by affinity chromatography over
a Ni21-nitrilotriacetic acid superflow column (Qiagen) and subsequent
gel filtration over a Superose column (23). For production of recombi-
nant RGS16 and mutants for GAP assays, mutations in the RGS16-
coding region were generated by polymerase chain reaction as described
previously (5) using pcDNA3-RGS16 as a template. These polymerase
chain reaction fragments were digested with EcoRI and XhoI and sub-
cloned in frame with glutathione S-transferase into the vector
pGEX4T1 (Amersham Pharmacia Biotech). Plasmids were transformed
into the BL21(DE3)pLysS bacterial strain, and protein production was
induced from a 1-liter mid-log phase culture with 0.1 mM isopropyl
b-D-thiogalactopyranoside for 3 h. Bacteria were pelleted and lysed by
freeze-thaw and sonication. Clarified supernatants were purified by
affinity chromatography on glutathione-agarose. The protein yield was
.4 mg/liter culture. Of note, we did not detect any difference in the GAP
activity of RGS16 with an amino-terminal His tag compared with an
amino-terminal glutathione S-transferase tag at a concentration as low
as 25 nM (data not shown). RGS16 antiserum (the generous gift of Carol
Beadling and Kendall Smith, Cornell University Medical College) was
raised against recombinant His-tagged human RGS16 (85% homology
to mouse). Antiserum to murine RGS16 was generated by injecting
RGS16 protein and complete Freund’s adjuvant into New Zealand
White rabbits (Cocalico Biologicals). Crude antisera (CT-265) were af-
finity purified with RGS16-coupled CNBr-agarose. Antibody elution
was performed with 100 mM glycine at pH 2.5 and was kept at 4 °C in
50% (NH4)2SO4 in phosphate-buffered saline, pH 7.4. As shown in Figs.
1C, 4, and 5, these antisera detected only transfected RGS16 (as op-
posed to other similarly sized, endogenous RGSs such as GAIP or RGS2)
in HEK293T cells used for signaling assays. The plasmid encoding rat
Gia1 and the affinity purified antibody that recognizes Gia1 have been
described previously (25).
Transfection, Metabolic Labeling with [3H]Palmitate, and Cell Frac-
tionation—COS-7 cells were grown to subconfluency in 75-cm2 tissue
culture flasks in complete DMEM supplemented with 10% fetal bovine
serum and transfected using 5 mg/flask plasmid DNA and the DEAE-
dextran method, as described (26). HEK293T cells were maintained in
complete DMEM and transfected using the calcium phosphate method.
Two days after transfection, cells were incubated for 2 h in serum-free
DMEM and then incubated in serum-free media containing 1% di-
methyl sulfoxide and 500 mCi/ml [3H]palmitic acid (American Radiola-
beled Chemicals, specific activity 60 Ci/mmol) for 1 h. Cells were har-
vested by scraping in 45 ml of ice-cold phosphate-buffered saline and
centrifuged at 500 3 g for 10 min. The cell pellets were stored at 270 °C
and then lysed, homogenized, and fractionated into particulate and
soluble fractions by centrifugation at 125,000 3 g for 1 h as described
before (27).
Immunoprecipitation, Immunoblotting, and Hydroxylamine Treat-
ment—400 mg of tritium-labeled protein from the particulate fraction
was immunoprecipitated with RGS16 antiserum in 500 ml of solubili-
zation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100
(v/v), 0.2% SDS (w/v) and 1 mM EDTA) overnight at 4 °C. The immune
complexes were purified by using protein A-Sepharose, as described
previously (25). The proteins were separated by SDS-PAGE using 12%
and gradient 8–16% Tris glycine polyacrylamide gels (Novex). Dupli-
cate gels containing the tritium-labeled immunoprecipitates were
treated either in 1 M Tris-HCl, pH 7.0, or 1 M hydroxylamine, pH 7.0, for
1 h at room temperature with gentle shaking. The gels were then
prepared for indirect fluorography (25). For immunoblots, 40 mg of
protein from each particulate and soluble fraction was separated by
SDS-PAGE and transferred to nitrocellulose paper. The proteins were
detected with the CT-265 antisera (1:4000 dilution) and enhanced
chemiluminescence (Amersham Pharmacia Biotech) as described by the
manufacturer.
Identification of [3H]Palmitate Incorporation by HPLC—Immunopre-
cipitates of tritium-labeled proteins were separated by SDS-PAGE, and
a band was excised at 17–22 kDa for RGS16 and 30–42 kDa for Gia1.
Fatty acids were cleaved from the proteins in the gel slices by base
treatment and were extracted into chloroform/methanol, using the
method of Linder et al. (28). The extracted fatty acids were dried under
nitrogen and dissolved in chloroform/methanol (2:1, v/v) with unlabeled
palmitic acid as carrier. The released fatty acids were separated by
reversed phase HPLC, using a C8 column (Bakerbond wide pore octyl,
4.6 3 250 mm). The column was equilibrated with water, 0.1% triflu-
oroacetic acid, 60% acetonitrile at a flow rate of 1 ml/min, and the
sample was applied. After 2 min, the column was eluted in a linear
gradient from 60 to 80% acetonitrile in 30 min. Fatty acid standards
(Sigma) were monitored by absorbance at 210 nm. Fractions were
collected every 30 s, and the radioactivity was determined by scintilla-
tion counting.
Cell-free Palmitoylation Assay—Cell-free palmitoylation was per-
formed as described by Caron (29) with modifications to optimize for
palmitoylation of RGS proteins. RGS protein (0.28 mg/ml) was incu-
bated at 37 °C in incubation buffer (20 mM Tris, pH 8.0, 0.3 M NaCl, 1
mM EGTA, 10 mM b-mercaptoethanol) with rat liver membrane extract
(0.35 mg/ml), 0.2 mM CoA, 2 mM ATP, and [9,10-3H]palmitate (180
mCi/ml, NEN Life Science Products, specific activity 52 Ci/mmol), in the
presence of protease inhibitors (pepstatin, 2 mg/ml; leupeptin, 2 mg/ml).
At different times, samples were frozen in a dry ice/ethanol bath and
stored at 280 °C for further analysis. Alternatively, the reaction was
stopped by addition of Laemmli sample buffer, and proteins were sub-
jected to one-dimensional PAGE using 10 mM dithiothreitol as the
reducing agent. Gels were stained with Coomassie Blue, photographed,
and prepared for fluorography with Amplify (Amersham Pharmacia
Biotech) and exposed to Kodak X-Omat AR film at 270 °C.
GAP Assays—Single turnover GTPase assays were performed as
described previously (5). The amount of labeled inorganic phosphate
released by 200 nM myristoylated Gia1 (Calbiochem) loaded with 1 mM
[32P]GTP (40–60 cpm/fmol) for 20 min at 30 °C was monitored after
equilibration at 4 °C and subsequent addition of MgSO4 (final 10 mM),
unlabeled substrate (100 mM GTP), and RGS protein. Ten aliquots were
withdrawn over 2 min, added to activated charcoal, and centrifuged,
and the radioactivity in the supernatants was determined by liquid
scintillation counting. The first point was set arbitrarily at 0, and the
amount of inorganic phosphate in the supernatant was calculated by
subtracting the zero time point value. The initial rate of GTP hydrolysis
was determined by a linear regression curve fitting these time points.
Rates in the absence of RGS protein averaged 0.3/min, and in the
presence of RGS16 averaged 1.5–6/min (depending on RGS
concentration).
Signaling Assays—To determine the activity of a Gi-linked pathway,
cAMP was measured in response to stimulation of endogenous b-adre-
nergic and somatostatin receptors in transfected HEK293T cells. One
day after transfection, cells were transferred to 12-well plates and
incubated overnight in media containing 2 mCi/ml [3H]adenine. The
cells were incubated for 30 min in HEPES/DMEM and then incubated
in HEPES/DMEM containing 1 mM 1-methyl-3-isobutylxanthine alone
or with 5 mM isoproterenol or 5 mM isoproterenol and 1 mM somatostatin
(Sigma) for 20 min. The reaction was stopped by aspirating the medium
and adding 1 ml of stopping buffer (0.2% (w/v) SDS, 50 mM Tris, pH 7.4,
and 1 mM cAMP). The cAMP was then separated by sequential chro-
matography over Dowex and alumina columns as described previously
(30). The cAMP accumulation was calculated as ([3H]cAMP cpm/
([3H]cAMP cpm 1 [3H]ATP cpm)) 3 103.
For evaluation of Gq-mediated signaling, two methods were em-
ployed. First, hormone-stimulated CREB activity of transfected m1
muscarinic receptors (1 mg, the gift of J. Silvio Gutkind, NIDR, National
Institutes of Health) was measured in HEK293T cells transfected with
a CREB-b-galactosidase reporter plasmid (1 mg, the gift of Roger Cone,
Oregon Health Sciences University) and 4 mg of empty vector or RGS16
expression plasmids for 12 h. Cells were serum-starved in DMEM, 0.1%
bovine serum albumin for an additional 24 h before the addition of 1 mM
carbachol (Sigma) for 6 h. Cell extracts were prepared by lysis in 50 ml
of reagent lysis buffer (Promega), a freeze-thaw cycle, and centrifuga-
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tion. 10 ml of the supernatant was incubated in diluted b-galactosidase
substrate (Galacton, Tropix). Luminescence was measured using a
Monolight 3010 Luminometer (Analytical Luminescence Laboratory).
Second, endogenous MAP kinase activity was measured in these cells
after carbachol stimulation. The cells were transfected with 1 mg of a
plasmid containing the cDNA for the m1 muscarinic receptor and 5 mg
vector or RGS16 expression plasmids using LipofectAMINE for 12 h
(Life Technologies, Inc.). After an additional 24 h of serum starvation,
cells were stimulated with 1 mM carbachol for 7 min and lysed in kinase
lysis buffer (20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM b-glycerophos-
phate, 1 mM dithiothreitol, 1 mM sodium orthovanadate, 1% Triton
X-100). Following centrifugation, equal amounts of supernatant protein
(50 mg) were resolved on 12% SDS gels and transferred to nitrocellulose.
Endogenous mitogen-activated protein (MAP) kinase activity was de-
tected with an antibody specific for the tyrosine 204-phosphorylated
form of ERK1 and -2 (Santa Cruz Biotechnology) diluted 1:300. Parallel
lysates were run in the same manner, and the blot was probed with an
antibody reactive to ERK1 and -2 (Santa Cruz Biotechnology) at a 1:500
dilution, to ensure that equal levels of ERK protein were present in each
sample. The relative activity of MAP kinase compared with unstimu-
lated cells was determined by densitometry of bands using IP Lab
Spectrum software (Eastman Kodak Co.).
For evaluation of Gqa(Q209L) activity, 1 mg of this expression plas-
mid (the gift of J. Silvio Gutkind) was co-transfected with 1 mg of
pLuc-CRE reporter plasmid (Stratagene) with or without RGS16 ex-
pression plasmids for 48 h. Cells were incubated in serum-free media
for 24 h before extraction. Luciferase activity was determined by adding
50 ml of luciferase substrate (Promega) to 10 ml of cell extract and
measuring luminescence as before. To normalize for transfection vari-
ations, 250 ng of cytomegalovirus-b-galactosidase plasmid was co-
transfected in each sample and the b-galactosidase activity determined.
Miscellaneous—Statisical analysis was performed using the Sig-
maPlot software. The HelicalWheel, PeptideStructure, and LineUp pro-
grams of GCG Software (55) were used for analysis of protein secondary
structure and homology.
RESULTS
Palmitoylation of RGS16—We investigated whether RGS16
underwent palmitoylation by expressing this protein in COS
cells followed by metabolic labeling with [3H]palmitate and
immunoprecipitation of the particulate fraction with affinity
purified CT-265, raised against RGS16. Tritium incorporation
was seen in a 23-kDa band that corresponds to the predicted
molecular weight of RGS16 (Fig. 1A). The incorporation of
tritium was analyzed further by treating gels that contain
immunoprecipitates of tritium-labeled RGS16 with either 1 M
Tris-HCl, pH 7, or 1 M hydroxylamine, pH 7, which breaks
thioester bonds. Hydroxylamine treatment released the tritium
signal, indicating that the modification was through a thioester
linkage (data not shown). We also analyzed the tritium-labeled
compound by treating immunoprecipitates of tritium-labeled
RGS16 under alkaline conditions to release lipids followed by
separation by high performance liquid chromatography
(HPLC) with a reverse phase C8 column. A protein that is
known to undergo palmitoylation, Gia1, was used as a control.
For both proteins, the tritium counts eluted with a peak at 13
min, near the palmitate standard elution time of 13.3 min (Fig.
2). A small peak at 19.5 min eluted after our last standard of
stearic acid (C18) and may represent a longer chain fatty acid.
These results show that RGS16 undergoes palmitoylation.
We also analyzed palmitoylation of RGS16 by performing an
in vitro palmitoylation assay on purified proteins (Fig. 1B).
Incubation of a rat liver membrane extract, [3H]palmitate,
coenzyme A, and ATP with purified RGS16 led to incorporation
of tritium into proteins with a relative molecular mass of 23
kDa.
We mutated two cysteine residues in the amino terminus
either singly or together because they were the likely sites of
palmitoylation for this protein (Table I). Tritium incorporation
was decreased in both of the single mutants, C2A and C12A,
with a greater decrease for the C12A mutant (Fig. 1A). The
double mutant (C2A/C12A) mutant showed only an insignifi-
cant amount of tritium incorporation that might have been due
to intracellular conversion of palmitate to tritium-labeled
amino acids. This result indicates that Cys-2 and Cys-12 are
critical for palmitoylation of RGS16 and are the likely sites of
the modification.
Membrane Localization of Palmitoylation-defective Mu-
tants—RGS16 was found in both the particulate and soluble
fractions after expression in HEK293 cells with about one-half
of the protein in the particulate fraction (Fig. 1C). Mutation of
Cys-2 and Cys-12 altered this distribution so that slightly more
of the protein was distributed to the soluble fraction. However,
a significant amount of protein was still found in the particu-
late fraction after a mutation that prevented palmitoylation.
This result indicates that palmitoylation was not critical for the
membrane attachment of this protein.
GAP Activity—The stoichiometry of palmitate incorporation
into recombinant RGS16 by the in vitro palmitoylation method
was too low to determine differences in enzymatic activity
between the palmitoylated and nonpalmitoylated forms of the
protein. Therefore, we tested whether the cysteine mutations
themselves, rather than palmitoylation, might affect the GAP
activity of RGS16 by determining the ability of the cysteine
mutants to accelerate GTP hydrolysis by Gia (Fig. 3). The GAP
activity of RGS proteins is also the most sensitive measure of
their affinity for Ga subunits because they bind with high
affinity to the transition state conformation of Gia subunits
and stabilize it during GTP hydrolysis rather than contributing
catalytic residues directly (6). The enzymatic activity of various
RGS4 mutants was directly proportional to the degree of sub-
FIG. 1. Palmitoylation and membrane localization of RGS16. A,
for in vivo studies, COS cells transfected with vector alone or with
cDNAs for the wild-type RGS16 or the indicated cysteine mutants were
metabolically labeled with [3H]palmitate and then homogenized and
separated into particulate and soluble fractions by centrifugation. The
particulate fraction was immunoprecipitated with a polyclonal antibody
to RGS16, followed by separation on SDS-PAGE on 12% acrylamide gels
and fluorography. The gels were exposed to Kodak MS film for 13 days
at 270 °C. B, for in vitro palmitoylation, the purified RGS16 protein
was incubated with [3H]palmitate, ATP, CoA, and a rat liver membrane
extract at 30 °C for 4 h. Aliquots were separated by SDS-PAGE and
analyzed by fluorography and exposed to Kodak X-Omat AR film for 1
day. C, HEK293T cells were transfected with vector alone or cDNAs for
wild-type RGS16 and the cysteine mutants and separated into partic-
ulate and soluble fractions. 40 mg of protein from each fraction was
separated on by SDS-PAGE and transferred to nitrocellulose paper.
Immunoblotting was performed with CT-265 and the Amersham Phar-
macia Biotech ECL kit for detection. Molecular mass markers in kDa
are shown to the left of each figure. The arrows indicate RGS16.
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strate binding in two previous studies (4, 5). Rates of single
turnover hydrolysis by Gia1 in the presence of a range of RGS
protein concentrations revealed no significant differences in
GAP activity between the wild-type protein and cysteine mu-
tants (Fig. 3). The rate of GTP hydrolysis by Gia1 in the pres-
ence of the double cysteine RGS16 mutant at various concen-
trations (Fig. 3B) varied from 88 to 102% of the control rate
(wild-type RGS16). Although we cannot rule out subtle effects
of the cysteine mutations themselves, no significant trend in
the defects was present. At least for this assay with soluble
RGS16 proteins, cysteines 2 and 12 did not contribute signifi-
cant contact points to the RGS-Gia1 interface.
Amino-terminal Cysteines Were Essential for Full in Vivo
Activity of RGS16—We tested a Gi-linked pathway to evaluate
the function of RGS16 palmitoylation. HEK293T cells that
contain endogenous somatostatin and b-adrenergic receptors
were transiently transfected with plasmids containing the
wild-type and palmitoylation-defective RGS16 proteins. The
somatostatin receptor activates Gia, leading to inhibition of
adenylyl cyclase. Isoproterenol, acting through the b-adrener-
gic receptor and Gsa, results in stimulation of adenylyl cyclase
and cAMP accumulation within the cell. Addition of somatosta-
tin and isoproterenol leads to a lower cAMP response than
treatment with isoproterenol alone (Fig. 4). Somatostatin was
less effective in decreasing the cAMP accumulation in response
to isoproterenol in cells transfected with the wild-type RGS16
compared with the vector-transfected cells. We saw some de-
crease in the cAMP accumulation because with transient trans-
fection not all cells are expressing the RGS protein. This result
is consistent with previous findings (8) and biochemical data
that show that RGS16 can increase the GTP hydrolysis of Gia
family proteins (22). cAMP accumulation in response to isopro-
terenol and somatostatin in cells expressing the nonpalmitoy-
lated C2A/C12A mutant was similar to the vector-transfected
cells. The single cysteine mutants showed an intermediate
response. Immunoblotting performed on the detergent-soluble
fraction of whole cell lysates from these transfections demon-
strated that wild-type and cysteine mutants were expressed at
similar levels (and thus were not likely to be aggregated as a
result of the various mutations) (Fig. 4, inset). In these cells,
the palmitoylation-deficient mutants were defective in their
ability to turn off a Gi-linked signaling pathway.
We investigated the ability of the wild-type RGS16 and its
cysteine mutants to inhibit a Gq-linked signaling pathway us-
ing two different methods. First, we measured the activity of
endogenous MAP kinase as reflected by phosphorylation of
ERK1–2 after carbachol stimulation in HEK293T cells trans-
fected with the m1 muscarinic receptor and RGS plasmids (32).
Phosphorylated ERK was detected by an antibody specific for
that form of the protein (Fig. 5A). We observed a nearly 5-fold
increase in MAP kinase activity in hormone-stimulated cells
(Fig. 5, A and B). Expression of wild-type RGS16 blocked acti-
vation to almost 25% of the activity of the vector-transfected
cells. In contrast, MAP kinase activity in the presence of the
RGS16 cysteine mutants was significantly different than with
wild-type RGS16, with activities 60–80% of vector-transfected
cells. The samples contained similar amounts of ERK1 and -2
and RGS proteins as detected by immunoblotting with the
appropriate antibodies (Fig. 5A, middle and bottom panels).
In a second assay of Gq-mediated signaling, we measured the
activity of a CREB-b-galactosidase reporter gene after stimu-
lation with carbachol in cells expressing the m1 muscarinic
receptor and the RGS16 proteins. The CREB-b-galactosidase
construct reflects activation of CREB resulting from an in-
crease in intracellular Ca21 or cAMP (33). We observed an
approximately 6.5-fold increase in reporter gene expression in
cells stimulated with carbachol, whereas expression of wild-
type RGS16 blunted the response by about 50% (Fig. 5C). In
contrast, b-galactosidase activity in cells transfected with
RGS16 single or double cysteine mutants was similar to vector-
transfected cells exposed to carbachol. Similar results were
seen with a double cysteine RGS4 mutant, but disparate ex-
pression levels compared with the wild-type protein made
quantitative analysis difficult. Thus, two independent assays
revealed that amino-terminal cysteine residues on RGS16 were
critical for its regulation of Gq-mediated signaling.
We tested the function of the acylation-deficient RGS16 mu-
tants, independent of GAP activity, by co-expression with a
constitutively active Gqa mutant (Q209L). The Gln to Leu
mutation leads to a constant GTP-bound state by virtue of its
deficient intrinsic GTPase activity (34). In HEK293T cells
transfected with Gqa(Q209L) and a reporter gene (a CREB-de-
pendent luciferase gene in these assays), we observed an al-
most 20-fold increase in activity compared with cells trans-
fected with reporter alone (Fig. 5D). In cells expressing
Gqa(Q209L) and wild-type RGS16, however, the response was
inhibited some 66%. Surprisingly, mutation of Cys-2 had little
effect on the ability of RGS16 to inhibit Gqa(Q209L)-induced
CREB activation, whereas the Cys-12 mutant-transfected cells
responded similarly to vector-transfected cells. Cells trans-
fected with the double cysteine mutant showed an intermediate
defect. This result suggests that palmitoylation may also affect
the ability of RGS proteins to act as effector antagonists for
Gqa.
DISCUSSION
RGS proteins regulate G protein signaling by increasing the
GTPase activity of heterotrimeric G protein a subunits, thus
augmenting deactivation. Amino-terminal cysteines of RGS16
were critical for its palmitoylation and regulation of signaling
in mammalian cells. Mutations that prevented palmitoylation
did not significantly alter GAP activity in vitro or subcellular
localization but did substantially decrease the RGS activity on
Gq- and Gi-linked pathways in vivo.
FIG. 2. HPLC analysis of the released 3H-labeled fatty acid.
COS cells were transfected with wild-type RGS16 or Gia1 and metabol-
ically labeled with [3H]palmitate. The cells were homogenized and
separated into particulate and soluble fractions, and immunoprecipita-
tion was performed on the particulate fractions. The samples were
separated by SDS-PAGE, and bands corresponding to the molecular
weight region of the proteins were excised from the gel. Gel bands were
treated with base to release the fatty acids, and extracted fatty acids
were applied to a reverse phase C8 column for HPLC. Fractions were
collected every 30 s, and radioactivity was determined by scintillation
counting. Elution times of myristate, C14:0, palmitate, C16:0, and
stearate, C18:0 standards are shown.
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Palmitoylation has previously been found on RGS-GAIP and
RGS4 (18, 20). These two proteins may represent prototypes of
distinct forms of RGS palmitoylation. RGS-GAIP and two other
RGS proteins, Ret-RGS1 and RGSZ1, contain a cluster of cys-
teines analogous to cysteine string proteins (35–37). Palmitoy-
lation occurs on the cysteine clusters of cysteine string pro-
teins, and this modification may be involved in attaching these
proteins to synaptic vesicle membranes (38–39). RGS-GAIP
incorporates [3H]palmitate and displays properties of tight
membrane association consistent with palmitoylation (18). Al-
though RGS-GAIP has been localized on clathrin-coated vesi-
cles, the role of palmitoylation in the targeting or function of
this protein is not known (19).
In contrast to RGS proteins with a cysteine string, RGS16,
RGS4, and RGS5 have only 2–3 cysteine residues outside the
RGS box, at their amino terminus (20). The amino termini of
these proteins are conserved with cysteines at residues 2 and
12 for all three (Table I). Structural modeling of a consensus
sequence of the amino terminus predicts that it forms an am-
phipathic a helix with Cys-2 and Cys-12 on the hydrophobic
face. Palmitoylation may aid the membrane attachment of the
protein, but other regions of the protein must be involved
because the absence of palmitoylation on RGS16 does not pre-
clude its retention at the membrane. Palmitoylation may orient
an a helix or possibly another conformation toward the mem-
brane and facilitate interactions between this region of the
RGS protein and another membrane-bound protein that recog-
nizes the conserved residues. Without palmitate, the protein
interactions may be adequate for attachment but inadequate
for functional interactions. The possibility of another protein
that targets RGS proteins to the membrane is suggested by a
recent study (40). We found that expression of a constitutively
active mutant, Gia2(Q205L), results in translocation of cytoso-
lic RGS4 to the plasma membrane (40). Paradoxically, RGS
proteins do not directly interact with a similar Gia1 mutant
(Q204L) (31). We also found that an RGS4 mutant (L159F),
which does not bind Gia in any nucleotide-binding state, trans-
located as well as the wild-type RGS4 protein. Thus, the mech-
anism whereby a protein-protein interaction may target an
TABLE I
Amino termini of RGS4 and RGS16
Protein 1 10 20 30 40 50
RGS16 MCRTLATFP NTCLERAKEF KTRLGIFLHK SELSSDTGGI SKFEWASKHN KERa
RGS4 MCKGLAGLP ASCLRSAKDM KHRLGFLLQK SDSCEHSSSH SKKDKV VT CQR
RGS5 MCKGLAALP HSCLERAKEI KIKLGILLQK PDSAVDLVIP YNEKPEKPAN GHK
Consensus MCKGLA-LP -SCLERAKE- K-RLGILLQK SDS--D---- SK-------N --Rb
a The cysteine residues that were mutated to alanines are in boldface.
b The consensus sequence was determined using the GCG software Lineup program for rat RGS4, mouse RGS16, and mouse RGS5. The dashes
indicate no conserved residues at that position.
FIG. 3. GAP activity of RGS16 mutants. GAP activity of RGS16
was monitored over 2 min as described under “Experimental Proce-
dures.” A, typical time course of GTP hydrolysis by Gia1 alone (open
circles) or in the presence of 6.25 nM RGS16 (wild-type, closed circles;
C2A, open triangles; C12A, closed triangles; C2A/C12A, rectangles). The
graph is representative of two such experiments. The inset shows a
Coomassie Blue-stained SDS gel of glutathione S-transferase-RGS16
proteins used in these studies. Molecular mass markers (kDa) are
indicated on the left (from top 64, 52, and 26). B, GAP activity of the
C2A/C12A mutant relative to wild-type activity at various concentra-
tions. The initial rate of GTP hydrolysis by Gia1 was 1.5–6/min depend-
ing on the RGS16 concentration. Bar graph shows the mean 6 S.E. of
three determinations expressed as the percentage of the wild-type rate.
FIG. 4. Effects of palmitoylation-defective RGS mutants on Gi-
mediated signaling. HEK293T cells expressing RGS16 mutants after
transient transfection were transferred to 12-well plates and then in-
cubated with [3H]adenine. Cells were treated with 1 mM 1-methyl-3-
isobutylxanthine alone or with 5 mM isoproterenol (ISO) or 5 mM isopro-
terenol and 1 mM somatostatin (SST) for 20 min, and cAMP
accumulation was determined. The decrease in cAMP accumulation in
the presence of somatostatin was calculated from the cAMP accumula-
tion with isoproterenol and somatostatin compared with cAMP accu-
mulation of isoproterenol alone expressed as a percentage. The cAMP
accumulation with isoproterenol alone was about 10-fold greater than
the control condition for each of the transfectants. The values shown are
the mean 6 S.E. of five experiments performed in triplicate (p 5 0.008
for wild-type (WT) versus vector (Vec) control; p , 0.05 for wild-type
versus C2A/C12A mutant using Student’s t test). Inset, an immunoblot
of 40 mg of protein from a detergent extract (1% v/v Triton X-100) of
whole cells using an antibody raised against human RGS16.
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RGS to the membrane is unclear at present.
The conserved RGS box alone is sufficient for GAP activity in
vitro (4, 41), but it is not sufficient for in vivo function (42, 43).
Although the RGS box is the primary site of RGS4 interaction
with Gia1 based on the crystal structure, this structure in-
cluded neither the 50 amino-terminal residues of RGS4 nor the
5 amino-terminal residues of Gia1, so it is not known if there
are other sites of interaction (6). Palmitoylation of Ga subunits,
which occurs on cysteine 3 for Gia family members, inhibited
the GAP activity of RGS proteins (44), indicating the impor-
tance of regions not seen in the crystal structure for the inter-
action between these proteins. Similarly, De Vries et al. (45)
found that deletion of the 10 most carboxyl-terminal residues of
Gia3 markedly diminished its interaction with RGS-GAIP in a
yeast two-hybrid assay. Recently published studies (43, 46)
show that RGS proteins may work not only through RGS and G
protein interactions but also through interactions with the
receptor complex, with the amino terminus of RGS proteins
imparting the receptor selectivity. A peptide consisting of the
first 33 residues of RGS4 blocked carbachol-dependent but not
cholecystokinin-dependent signaling, both of which are medi-
ated by Gq proteins (43). Interestingly, a peptide with the
cysteines at positions 2, 12, and 33 replaced by alanines was
100-fold less effective (43). Palmitoylation and tethering of the
RGS protein to the membrane could establish a protein confor-
mation critical for interactions with both G proteins and
receptors.
Our results with the constitutively active Gqa(Q209L) mu-
tant suggest that palmitoylation may alter another function of
RGS proteins. Inhibition of CREB activation induced by
Gqa(Q209L) is probably through effector antagonism because
RGS proteins do not interact with or stimulate the GTPase
activity of a similar Gia mutant (Gia1Q204L) (31). Both RGS4
and RGS-GAIP have been shown to block the interaction be-
tween Gqa-GTP and its effector, phospholipase Cb (47). In
addition, a peptide with the amino-terminal sequence of RGS4
could block the interactions of Gqa and phospholipase Cb (45).
The reason for the partial function of the double mutant in our
assays is unclear; perhaps the Cys-2 mutation actually en-
hances interaction with the Gqa protein in this GTP-bound
conformation and serves to counteract the effect of the Cys-12
mutation. In fact, we cannot exclude structural differences of
these mutants in vivo (independent of lipid modification) even
though the cysteine mutations did not affect the catalytic
power of RGS16 in vitro. For Gqa, amino-terminal cysteine
residues are important for coupling to the effector, phospho-
lipase Cb, independent of their palmitoylation (48). For RGS
proteins, these cysteine residues may directly interact with Ga
proteins because neither the stoichiometry of palmitoylated to
unpalmitoylated protein nor the kinetics of palmitate turnover
on RGS proteins during the GTPase cycle is known.
Palmitoylation of RGS may also regulate Ga interactions
independently of its effect on the protein-protein interface sim-
ply by targeting RGS proteins to membrane microdomains that
mids, or empty vector as indicated. 48 h after transfection and serum
starvation, cells were stimulated with 1 mM carbachol for an additional
6 h. Cell extracts were prepared and b-galactosidase activity measured
as described under “Experimental Procedures.” Bar graphs represent
the fold increase in activity over unstimulated cells (mean 6 S.E. of
three independent experiments). D, CREB activity with expression of a
constitutively active Gqa. HEK293T cells were transfected with plas-
mids encoding a CREB-Luciferase reporter, Gqa(Q209L) (all except lane
1), and cDNAs for RGS16 (wild-type or mutants) or empty vector as
shown. After 48 h of serum starvation, cell extracts were prepared, and
the luciferase activity therein was measured as described. Bar graphs
represent the fold increase in activity over vector-transfected cells
(mean 6 S.E. of three independent experiments).
FIG. 5. RGS16 cysteine mutants are defective in modulating
Gq-coupled signaling. A and B, endogenous MAP kinase activity.
HEK293T cells transfected with an m1 muscarinic receptor plasmid
and vector alone or with the cDNA for the wild-type RGS16 or the
cysteine mutants. After 24 h of serum starvation, the cells were stim-
ulated with 1 mM carbachol for 7 min and lysed. A, equal amounts of
protein were separated on SDS-PAGE gels and immunoblotted for
phospho-ERK1–2 (top), total ERK1–2 (middle), and RGS16 (bottom). B,
bar graph showing mean 6 S.E. from three independent experiments of
the fold increase in MAP kinase activity of stimulated cells over un-
stimulated cells (lane 1) as determined by densitometry. C, CREB
activity. HEK293T cells were transiently transfected with the m1 re-
ceptor, CREB-b-galactosidase and wild-type or mutant RGS16 plas-
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also hold Ga subunits and possibly other signaling components.
Receptors, Ga subunits, and RGS proteins all undergo palmi-
toylation. One type of microdomain has been characterized by
its detergent insolubility, low density on centrifugation, and
enrichment of cholesterol and sphingolipids (49). These choles-
terol/sphingolipid rafts have a high affinity for saturated, long
chain fatty acids such as palmitate (50), and many proteins
found in rafts are palmitoylated (51). Cysteine residues that
undergo palmitoylation on endothelial nitric-oxide synthase,
p56lck, and GAP-43 are critical for targeting those proteins to
these membrane domains (52–54). Concentration of these low
abundance proteins to small areas within the membrane may
be necessary for their action within cells. These domains may
differ between mammalian cells and yeast cells to explain the
results of Srinivasa and colleagues (20), who found relatively
preserved activity and plasma membrane localization of palmi-
toylation-defective RGS4 in yeast.
The regulation of RGS proteins in cells is poorly understood.
Their powerful catalytic activities suggest that they must be
carefully regulated. Transcriptional control is likely to repre-
sent one means of modulating RGS expression (3), but the
reversible nature of palmitoylation would also allow it to con-
trol the function of the protein. Palmitate on Ga turns over
upon activation (14–16) and inhibits RGS activity (44). Like-
wise, palmitoylation, with its inherent reversibility, may prove
to harness the action of RGS proteins on Ga subunits.
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